CEO 360 Degree Perspective - Global Pharmaceuticals & Biotechnology Industry

 

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

This research service presents the CEO 360 Degree Perspective for the global pharmaceuticals and biotechnology industry in 2009. It is an amalgamation of research from more than 50 Pharmaceutical research services generated by Frost & Sullivan, customer research findings based on approximately 1,000 end-user interviews approximately 50,000 hours of analyst research, in the last 2 years. Global healthcare analysts from Frost & Sullivan have contributed their market knowledge to cover the most important issues that are relevant in the healthcare industry today. The report also includes research findings from econometric, advanced technology and several other business divisions of Frost & Sullivan.

Table of Contents

CEO 360 Degree Perspective - Global Pharmaceuticals & Biotechnology Industry, Pharmaceuticals & Biotechnology IndustryIntroductionTitleDisclaimerCertificationResearch Overview and Background360 Degree Perspective and the Complex Business UniverseTable of ContentsGlobal PerspectiveGlobal PerspectiveShifting Global Clinical Trial DynamicsShift In Growth From Mature Markets To Emerging MarketsIntegrated Industry PerspectiveIntegrated Industry PerspectiveAdaptation To Changing Business ModelsConsolidation of Pfizer and WyethConvergence of Healthcare Allows for PersonalizationMove from Transactional to Strategic Outsourcing Partnerships Encourages Standardization of LIMSTechnology PerspectiveTechnology PerspectiveOral Oncology Drugs Increasing in ImportanceAdvances in Genomics Promotes Healthcare Paradigm Shift Effective Screening Methods to Select the Most Promising Drug CandidatesGrowth of Vaccines Market Boosting Technology InnovationGene Therapy Driving MarketEconomic PerspectiveEconomic PerspectiveVenture Capital Investment in U.S. Biotechnology has Decreased to Levels Not Seen Since 2002Decreasing Number of Biotech IPO's due to Economic DownturnRestructuringContinued Healthcare Spending GrowthCompetitive PerspectiveCompetitive PerspectiveCompanies Transforming to Comprehensive Solution ProvidersRepositioning of Platform Technology Providers in Response to Biomarker Discovery and Diagnostics Development Expansion of Biosimilars Alters Industry LandscapeCustomer PerspectiveCustomer PerspectivePower Patient GenerationeDetailing To Assume More SignificanceMedical Tourism – Emerging Hot SpotsBest Practices PerspectiveBest Practices PerspectiveGreen Chemistry InitiativesFocus on Diseases with High Unmet Needs and Special DesignationsLower Cost Drugs for Developing CountriesEmploying Hybrid Business ModelsAbout Frost & SullivanFrost & Sullivan




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 10-Nov-17

Region : Global

Release Date : 10-Nov-17

Region : Global

Release Date : 09-Nov-17

Region : Global

Release Date : 03-Nov-17

Region : Global

Release Date : 31-Oct-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.